Adial Pharmaceuticals director James W. Newman Jr. resigns from Board effective Jan 5, 2026

ADIAL PHARMACEUTICALS, INC.

James W. Newman Jr. resigned as director and member of Audit and Compensation Committees, effective January 5, 2026.
No disagreement with company operations, policies or practices cited.
No replacement has been announced.

item 5.02

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-001790

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.